Problem $5($Recommended: review slides $65-70)$

Alpha acquired $\backslash (70\backslash \%\backslash )$ of Beta's shares on July $\backslash (1,\backslash$underline$\{2025\}\backslash )$ paying $\backslash (\backslash$$ $750,000\backslash )$ in equity securities$.$ The remaining $\backslash (30\backslash \%\backslash )$ of Beta's shares traded closely near an average price that totaled $\backslash (\backslash$$ $320,000\backslash )$ both before and after Alpha's acquisition.

In reviewing the acquisition, Alpha assigned a $\backslash (\backslash$$ $100,000\backslash )$ fair value to a patent recently developedby Beta, even though it was not recorded within the financial records of the subsidiary. This patent is anticipated to have a remaining life of five years. Also, Buildings recorded in Beta's book were undervalued by $\backslash (\backslash$$ $30,000\backslash )$ with remaining life of $10$ years.

Alpha uses the equity method to account for the Investment in Beta.

The following financials are available for these two companies for $2025.$ In addition, the subsidiary's income was earned uniformly thought the year. Subsidiary dividend payments were made quarterly.

Using the information provided above, please answer the following questions:

$1.$ What is the goodwill at the acquisition date?

$2.$ What is the proportion of goodwill assigned to NCI $?$

$3.$ What is the ECOBV amortization for $2025?$

$4.$ What is the balance sheet NCI on December $31,2025?$